---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-056665"
form_type: "8-K"
ticker: "KNSA"
cik: "0001730430"
company_name: "Kiniksa Pharmaceuticals International, plc"
filed_at: "2025-06-05T23:59:59+00:00"
generated_at: "2026-05-19T22:20:04.775738+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Kiniksa details Phase 2/3 trial design for KPL-387 in recurrent pericarditis; initiation mid-2025

## Summary
- Phase 2/3 trial: dose-focusing portion enrolls up to ~80 patients; pivotal portion up to ~85.
- Primary endpoint: time to treatment response at Week 24 (Phase 2) and time to first recurrence (Phase 3).
- Phase 1 single ascending dose data support monthly subcutaneous dosing with liquid formulation.
- Phase 2 data expected in second half of 2026.
- Corporate presentation at Jefferies 2025 Global Healthcare Conference at 12:50 pm ET on June 5.

## SEC filing metadata
- accession: 0001104659-25-056665
- form_type: 8-K
- ticker: KNSA
- cik: 0001730430
- company_name: Kiniksa Pharmaceuticals International, plc
- filed_at: 2025-06-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730430/000110465925056665/0001104659-25-056665-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730430/000110465925056665/tm2517185d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-056665
- JSON: https://secwatch.observer/filing/0001104659-25-056665.json
- Plain text: https://secwatch.observer/filing/0001104659-25-056665.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.